作者
Eva Versteijne, Mustafa Suker, Karin Groothuis, Janine M Akkermans-Vogelaar, Marc G Besselink, Bert A Bonsing, Jeroen Buijsen, Olivier R Busch, Geert-Jan M Creemers, Ronald M van Dam, Ferry ALM Eskens, Sebastiaan Festen, Jan Willem B de Groot, Bas Groot Koerkamp, Ignace H de Hingh, Marjolein YV Homs, Jeanin E van Hooft, Emile D Kerver, Saskia AC Luelmo, Karen J Neelis, Joost Nuyttens, Gabriel MRM Paardekooper, Gijs A Patijn, Maurice JC van der Sangen, Judith de Vos-Geelen, Johanna W Wilmink, Aeilko H Zwinderman, Cornelis J Punt, Casper H van Eijck, Geertjan van Tienhoven, Dutch Pancreatic Cancer Group
发表日期
2020/6/1
期刊
Journal of Clinical Oncology
卷号
38
期号
16
页码范围
1763-1773
出版商
American Society of Clinical Oncology
简介
PURPOSE
Preoperative chemoradiotherapy may improve the radical resection rate for resectable or borderline resectable pancreatic cancer, but the overall benefit is unproven.
PATIENTS AND METHODS
In this randomized phase III trial in 16 centers, patients with resectable or borderline resectable pancreatic cancer were randomly assigned to receive preoperative chemoradiotherapy, which consisted of 3 courses of gemcitabine, the second combined with 15 × 2.4 Gy radiotherapy, followed by surgery and 4 courses of adjuvant gemcitabine or to immediate surgery and 6 courses of adjuvant gemcitabine. The primary end point was overall survival by intention to treat.
RESULTS
Between April 2013 and July 2017, 246 eligible patients were randomly assigned; 119 were assigned to preoperative chemoradiotherapy and 127 to immediate surgery. Median overall survival by intention to treat was 16.0 months with …
学术搜索中的文章
E Versteijne, M Suker, K Groothuis… - Journal of Clinical Oncology, 2020